Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
Authors
Keywords
-
Journal
MEDIATORS OF INFLAMMATION
Volume 2017, Issue -, Pages 1-15
Publisher
Hindawi Limited
Online
2017-06-02
DOI
10.1155/2017/8909834
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
- (2017) Dennis Falzon et al. EUROPEAN RESPIRATORY JOURNAL
- The Intelligent Control System and Experiments for an Unmanned Wave Glider
- (2017) Yulei Liao et al. PLoS One
- Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT
- (2016) H. Hoffmann et al. CLINICAL MICROBIOLOGY AND INFECTION
- Use of several immunological markers to model the probability of active tuberculosis
- (2016) Elisa Petruccioli et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- First evaluation of QuantiFERON-TB Gold Plus performance in contact screening
- (2016) Lucia Barcellini et al. EUROPEAN RESPIRATORY JOURNAL
- First independent evaluation of QuantiFERON-TB Plus performance: TABLE 1
- (2016) Lucia Barcellini et al. EUROPEAN RESPIRATORY JOURNAL
- Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices
- (2016) Masoud Dara et al. EUROPEAN RESPIRATORY JOURNAL
- Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis
- (2016) Elisa Petruccioli et al. EUROPEAN RESPIRATORY JOURNAL
- Safety of secukinumab in the treatment of psoriasis
- (2016) Andrew Blauvelt Expert Opinion On Drug Safety
- Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
- (2016) Silvia Minozzi et al. Expert Opinion On Drug Safety
- First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus
- (2016) Elisa Petruccioli et al. JOURNAL OF INFECTION
- Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
- (2016) Johannes W J Bijlsma et al. LANCET
- A blood RNA signature for tuberculosis disease risk: a prospective cohort study
- (2016) Daniel E Zak et al. LANCET
- Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection
- (2016) G. Delogu et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis
- (2016) Fabrizio Cantini et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Addressing diabetes mellitus as part of the strategy for ending TB
- (2016) Anthony D. Harries et al. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
- TB vaccine development and the End TB Strategy: importance and current status
- (2016) Helen A. Fletcher et al. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
- T-cell activation is an immune correlate of risk in BCG vaccinated infants
- (2016) Helen A. Fletcher et al. Nature Communications
- The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
- (2016) Rein M. G. J. Houben et al. PLOS MEDICINE
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
- (2016) Laura C. Coates et al. Arthritis & Rheumatology
- Evaluation of QuantiFERON-TB Gold Plus for Detection of Mycobacterium tuberculosis infection in Japan
- (2016) Lina Yi et al. Scientific Reports
- Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study
- (2015) Jean-Pierre Zellweger et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
- (2015) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
- (2015) Fabrizio Cantini et al. AUTOIMMUNITY REVIEWS
- Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
- (2015) Vivian P. Bykerk et al. CLINICAL RHEUMATOLOGY
- Towards tuberculosis elimination: an action framework for low-incidence countries
- (2015) Knut Lönnroth et al. EUROPEAN RESPIRATORY JOURNAL
- Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus
- (2015) Katharina Ronacher et al. IMMUNOLOGICAL REVIEWS
- Co-evolution ofMycobacterium tuberculosisandHomo sapiens
- (2015) Daniela Brites et al. IMMUNOLOGICAL REVIEWS
- Cytokine and lipid mediator networks in tuberculosis
- (2015) Katrin D. Mayer-Barber et al. IMMUNOLOGICAL REVIEWS
- Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey
- (2015) Fabrizio Cantini et al. International Journal of Rheumatic Diseases
- Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis
- (2015) Elisa Petruccioli et al. JOURNAL OF INFECTION
- Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks
- (2015) N. Takahashi et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons
- (2015) Adam Penn-Nicholson et al. TUBERCULOSIS
- Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial
- (2015) Arthur Kavanaugh et al. ARTHRITIS CARE & RESEARCH
- Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
- (2015) Ryoko Sakai et al. ARTHRITIS RESEARCH & THERAPY
- Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
- (2015) Robert E. Kalb et al. JAMA Dermatology
- American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- (2015) Michael M. Ward et al. Arthritis & Rheumatology
- Biomarkers Can Identify Pulmonary Tuberculosis in HIV-infected Drug Users Months Prior to Clinical Diagnosis
- (2015) Rosa Sloot et al. EBioMedicine
- Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
- (2014) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
- (2014) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Combined Use of Mycobacterium tuberculosis–Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis
- (2014) Virginie Rozot et al. CLINICAL INFECTIOUS DISEASES
- Distinct, Specific IL-17- and IL-22-Producing CD4+ T Cell Subsets Contribute to the Human Anti-Mycobacterial Immune Response
- (2014) T. J. Scriba et al. JOURNAL OF IMMUNOLOGY
- Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients
- (2014) Teresa Chiacchio et al. JOURNAL OF INFECTION
- Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial
- (2014) J. M. Kremer et al. JOURNAL OF RHEUMATOLOGY
- Assessment of the novel T-cell activation marker–tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study
- (2014) Damien Portevin et al. LANCET INFECTIOUS DISEASES
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data
- (2014) Yasuharu Nakashima et al. Modern Rheumatology
- In search of a new paradigm for protective immunity to TB
- (2014) Cláudio Nunes-Alves et al. NATURE REVIEWS MICROBIOLOGY
- The ongoing challenge of latent tuberculosis
- (2014) H. Esmail et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
- (2014) Alejandro Souto et al. RHEUMATOLOGY
- Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
- (2014) Alan Kivitz et al. ARTHRITIS CARE & RESEARCH
- Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients
- (2014) Joerg Wendler et al. ARTHRITIS RESEARCH & THERAPY
- Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
- (2014) Radha Gopal et al. PLoS Pathogens
- Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis
- (2014) Teresa Prezzemolo et al. Frontiers in Immunology
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
- (2013) Michael Schiff et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
- (2013) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Autophagy in Mycobacterium tuberculosis infection: A passepartout to flush the intruder out?
- (2013) Delia Goletti et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Mycobacterium tuberculosis-specific CD8+T cells are functionally and phenotypically different between latent infection and active disease
- (2013) Virginie Rozot et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-1 Promotes Antimicrobial Immunity in Macrophages by Regulating TNFR Signaling and Caspase-3 Activation
- (2013) P. Jayaraman et al. JOURNAL OF IMMUNOLOGY
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- (2013) Dominique Baeten et al. LANCET
- IGRAs – The gateway to T cell based TB diagnosis
- (2013) Hilary S. Whitworth et al. METHODS
- Randomised Clinical Trial Investigating the Specificity of a Novel Skin Test (C-Tb) for Diagnosis of M. tuberculosis Infection
- (2013) Henrik Aggerbeck et al. PLoS One
- Demographic Variables for Wild Asian Elephants Using Longitudinal Observations
- (2013) Shermin de Silva et al. PLoS One
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2013) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study
- (2012) Edward Clark Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
- (2012) Vivian P Bykerk et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
- (2012) Juan J Gomez-Reino et al. ANNALS OF THE RHEUMATIC DISEASES
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
- (2012) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
- (2012) T.-F. Tsai et al. BRITISH JOURNAL OF DERMATOLOGY
- Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection
- (2012) Maria Nikolova et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
- (2012) Dragos Bumbacea et al. EUROPEAN RESPIRATORY JOURNAL
- Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections
- (2012) Anne Isvy et al. JOINT BONE SPINE
- Knee tuberculosis under rituximab therapy for rheumatoid arthritis
- (2012) Sébastien Ottaviani et al. JOINT BONE SPINE
- Specific T Cells Restore the Autophagic Flux Inhibited by Mycobacterium tuberculosis in Human Primary Macrophages
- (2012) Elisa Petruccioli et al. JOURNAL OF INFECTIOUS DISEASES
- Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
- (2012) V. Strand et al. RHEUMATOLOGY
- The effects of rituximab therapy on released interferon- levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection
- (2012) Y.-M. Chen et al. RHEUMATOLOGY
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
- (2012) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
- (2011) M. H. Buch et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
- (2011) Yusuf Yazici et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
- (2011) J. M. Kremer et al. ANNALS OF THE RHEUMATIC DISEASES
- Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
- (2011) T. Koike et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
- (2011) J. Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study
- (2011) Jérémie Sellam et al. ARTHRITIS AND RHEUMATISM
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
- (2011) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial
- (2011) Maria W. Greenwald et al. ARTHRITIS AND RHEUMATISM
- Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection
- (2011) Bisweswar Nandi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Functional Capacity of Mycobacterium tuberculosis-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load
- (2011) C. L. Day et al. JOURNAL OF IMMUNOLOGY
- Safety and Effectiveness of Rituximab in Patients with Rheumatoid Arthritis Following an Inadequate Response to 1 Prior Tumor Necrosis Factor Inhibitor: The RESET Trial
- (2011) BOULOS HARAOUI et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis: An Open-label Randomized Controlled Trial
- (2011) KENSUKE KUME et al. JOURNAL OF RHEUMATOLOGY
- Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis
- (2011) Molebogeng X Rangaka et al. LANCET INFECTIOUS DISEASES
- Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection
- (2011) K. A. Millington et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study
- (2011) T. Takeuchi et al. RHEUMATOLOGY
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
- (2011) Hans-Peter Tony et al. ARTHRITIS RESEARCH & THERAPY
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
- (2010) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
- (2010) G. R. Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
- (2010) P. P. Tak et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
- (2010) J.-E. Gottenberg et al. ARTHRITIS AND RHEUMATISM
- Role of Th17 cells in human autoimmune arthritis
- (2010) Jan Leipe et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- How tumour necrosis factor blockers interfere with tuberculosis immunity
- (2010) J. Harris et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
- (2010) I. Solovic et al. EUROPEAN RESPIRATORY JOURNAL
- Mycobacterium bovis BCG-Specific Th17 Cells Confer Partial Protection against Mycobacterium tuberculosis Infection in the Absence of Gamma Interferon
- (2010) T. M. Wozniak et al. INFECTION AND IMMUNITY
- Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection withMycobacterium tuberculosis
- (2010) Andrea Cruz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial
- (2010) P. J. MEASE et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
- (2010) Hisashi Yamanaka et al. Modern Rheumatology
- Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
- (2010) A. Rubbert-Roth et al. RHEUMATOLOGY
- Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
- (2010) X. Mariette et al. RHEUMATOLOGY
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
- (2009) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
- (2009) R Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement
- (2009) U. Mack et al. EUROPEAN RESPIRATORY JOURNAL
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
- (2009) Clifton E. Barry et al. NATURE REVIEWS MICROBIOLOGY
- Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice
- (2009) Yasuhiko Hirabayashi et al. RHEUMATOLOGY INTERNATIONAL
- The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
- (2008) M Schiff et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders
- (2008) Rogier M. Thurlings et al. ARTHRITIS AND RHEUMATISM
- Mycobacterial and Other Serious Infections in Patients Receiving Anti–Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network
- (2008) Kevin L. Winthrop et al. CLINICAL INFECTIOUS DISEASES
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
- (2008) Josef S Smolen et al. LANCET
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2008) Norihiro Nishimoto et al. Modern Rheumatology
- Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis
- (2008) D. McGonagle et al. RHEUMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started